Amneal And mAbxience Ally On Denosumab In US

Deal Agreed Between Partners On Biosimilar Candidates Referencing Prolia And Xgeva

Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.

Amneal HQ building sign
Amneal has added two denosumab biosimilars to its pipeline • Source: Shutterstock

Amneal and mAbxience have announced a further collaboration that will see Amneal gain US rights to mAbxience’s denosumab biosimilars. The two denosumab products reference Amgen’s Prolia and Xgeva brands that treat bone metastasis from cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. The partnering companies have previously allied on a bevacizumab biosimilar that Amneal currently markets in the US.

Noting that mAbxience has “over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals,” Amneal said that...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business